Bixia X. Tang

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 116 publications

Features of tumor microenvironment in HER2-positive urothelial carcinoma and its implications for immunotherapy resistance.

Features of tumor microenvironment in HER2-positive urothelial carcinoma and its implications for immunotherapy resistance.

Journal: BMC cancer

Published: April 11, 2026

Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study.

Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study.

Journal: BMC medicine

Published: January 20, 2026

Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.

Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.

Journal: JAMA oncology

Published: January 02, 2026

Advances in antibody-drug conjugates for urothelial carcinoma treatment.

Advances in antibody-drug conjugates for urothelial carcinoma treatment.

Journal: Cancer biology & medicine

Published: September 23, 2025

EWAS Open Platform 2026: a deeply integrated resource for epigenome-wide association studies.

EWAS Open Platform 2026: a deeply integrated resource for epigenome-wide association studies.

Journal: Nucleic acids research

Published: September 15, 2025

Genome Variation Map: a platform for the analysis and integration of genomic variation.

Genome Variation Map: a platform for the analysis and integration of genomic variation.

Journal: Nucleic acids research

Published: September 15, 2025

A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma.

A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma.

Journal: Nature communications

Published: August 08, 2025

TCR and BCR repertoire analysis reveals distinct signatures between benign and malignant ovarian tumors.

TCR and BCR repertoire analysis reveals distinct signatures between benign and malignant ovarian tumors.

Journal: Frontiers in oncology

Published: May 22, 2025

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.

Journal: Cancer management and research

Published: February 05, 2025

HiLand Resource: A Comprehensive Database of Highland Human Populations.

HiLand Resource: A Comprehensive Database of Highland Human Populations.

Journal: Genomics, proteomics & bioinformatics

Published: January 21, 2025

Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights.

Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights.

Journal: Journal for immunotherapy of cancer

Published: January 19, 2025

A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy.

A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy.

Journal: World journal of urology

Published: November 10, 2024

Showing 1-12 of 116

Last Updated: 09/26/2026